15 results about "EGFR Antibody" patented technology

The present application provides a polypeptide as CDRs in an antibody light chain, light chain variable region or light chain, which is capable of constructing an antibody with CDRs in an antibody heavy chain, heavy chain variable region or heavy chain having binding affinity and / or specificity to different target proteins (antigens), the antibody retaining binding affinity and / or specificity to the target proteins (antigens) and biological activity. The present application also provides an anti-B7-H3 and / or EGFR antibody comprising the polypeptide as a light chain variable region or light chain.

The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.

This disclosure relates to anti-TROP2 / EGFR antibodies, and antibody drug conjugates derived therefrom, wherein the antibodies specifically bind to at least two different antigens EGFR and TROP2.

The present disclosure relates to the use of a KRAS G12D inhibitor in combination with an anti-EGFR antibody in the manufacture of a medicament for the treatment of a solid tumor. In particular, the present disclosure relates to the use of a KRAS G12D inhibitor in combination with an anti-EGFR antibody, or an antigen-binding fragment thereof, in the manufacture of a medicament for the treatment of a solid tumor having a KRAS G12D mutation.

Provided are an anti-EGFR antibody or an antigen-binding fragment thereof and a use thereof. The antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3. The light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein LCDR1 comprises an amino acid sequence as shown in SEQ ID NO: 1, LCDR2 comprises an amino acid sequence as shown in SEQ ID NO: 2, and LCDR3 comprises an amino acid sequence as shown in SEQ ID NO: 3. Further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and transformant for expressing the antibody or the antigen-binding fragment thereof, and a treatment and diagnosis / detection method and use of the antibody or the antigen-binding fragment thereof.

This invention discloses an anti-EGFR antibody mutant with antioxidant properties and its applications, belonging to the field of biotechnology. To improve the antioxidant activity of antibodies and prevent oxidative degradation, existing anti-EGFR antibodies are analyzed and mutated to enhance their antioxidant performance and structural stability while maintaining superior affinity for the EGFR antigen. Furthermore, this mutant is assembled with an anti-c-Met antibody to form a heterodimer. The resulting bispecific antibody exhibits high affinity, greater structural stability, and stronger antioxidant capacity, thus showing promising market application prospects.

This invention discloses a highly specific EGFR antibody mutant and its applications, relating to the field of biotechnology. The EGFR antibody mutant is obtained by mutating cetuximab using any three or four of the following mutations: H52D, H104D, H101M, H56E, H99D, L50D, and L34Y. By designing mutations at multiple different sites in the amino acid sequence of cetuximab, this invention enables the antibody mutant to specifically recognize drug-resistant mutations in the extracellular region of the EGFR antigen and reduce recognition of unmutated EGFR antigens, thereby improving the applicability and safety of subsequent immunotherapy products, particularly CAR-T, CAR-NK, or engineered antibody drugs.

Production of a higher-purity intermediate of a radioactive antibody drug. The production method of the present invention includes: an adsorption step of adsorbing a composition containing the intermediate onto a stationary phase for hydrophobic chromatography; and a purification step of eluting the intermediate from the stationary phase. The intermediate is a complex of a 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (PCTA) and an anti-epidermal growth factor receptor antibody (anti-EGFR antibody).

This invention belongs to the field of biomedicine and relates to an anti-EGFR monoclonal antibody, its bispecific antibody, pharmaceutical composition, and uses. Specifically, this invention relates to an anti-EGFR antibody or its antigen-binding fragment. This invention also relates to an anti-EGFR-anti-Met bispecific antibody. Both the anti-EGFR monoclonal antibody and the bispecific antibody of this invention exhibit good antitumor activity.

Provided in the present invention is a polypeptide, which is used as an antibody light chain, a light chain variable region, or CDRs in a light chain. The polypeptide can be used for constructing an antibody with an antibody heavy chain, a heavy chain variable region, or CDRs in a heavy chain having binding affinity and / or specificity for different target proteins (antigens). The antibody retains the binding affinity and / or specificity for the target proteins (antigens) and biological activity. Also provided in the present invention is an anti-B7-H3 and / or EGFR antibody comprising the polypeptide as a light chain variable region or a light chain.

The present disclosure relates to bispecific antibodies comprising anti-CDCPl antibody regions and anti-EGFR antibody regions, drug conjugates comprised of one or morecytotoxic agents linked to the bispecific, and methods of making and using these molecules for the treatment of cancer and other diseases. Also disclosed here are monospecific antibodies comprising anti- CDCPl antibody regions. The anti-CDCPl antibody region comprises a single variable domain on a heavy chain (VHH) or a fragment thereof.

The application discloses a VirusTAC platform for targeted degradation of tumor cell membrane protein EGFR and psoriasis extracellular pathogenic factor IL17A and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an immunoglobulin Fc region, the Fc regions corresponding to the first polypeptide chain and the second polypeptide chain are associated by heterodimerization mutation; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain EGFR antibody or IL17A antibody. The platform realizes precise degradation of tumor-related membrane proteins and extracellular proteins by constructing a chimera of a natural ligand and a targeting antibody, and by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4.

The present invention belongs to the field of biomedicine and relates to an anti-EGFR monoclonal antibody, a bispecific antibody thereof, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to an anti-EGFR antibody or an antigen-binding fragment thereof. The present invention further relates to an anti-EGFR-anti-Met bispecific antibody. The anti-EGFR monoclonal antibody and the bispecific antibody of the present invention have good anti-tumor activity.

The present invention belongs to the field of biomedicine and relates to an anti-EGFR monoclonal antibody, a bispecific antibody thereof, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to an anti-EGFR antibody or an antigen-binding fragment thereof. The present invention further relates to an anti-EGFR-anti-Met bispecific antibody. The anti-EGFR monoclonal antibody and the bispecific antibody of the present invention have good anti-tumor activity.